Indevus Pharmaceuticals, Inc. submits new drug to FDAShares of Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) are edging higher in pre-market trading after the specialty pharmaceutical company reported it has submitted a new drug application to the U.S. Food and Drug Administration for the approval of NEBIDO intramuscular injection. NEBIDO is a long-acting testosterone therapy intended to treat male patients with primary and secondary hypogonadism. Shares of Indevus gained $0.25, or 3.52%, to $7.35 in pre-market trading. spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer
|
Research
|
